No photo of Priya U Kumthekar

View Scopus Profile

Priya U Kumthekar

  • 371 Citations
20102025
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Research Interests

My interests include treating primary brain tumors such as gliomas and meningiomas. I also have a specific interest in metastatic disease to the brain from systemic cancers such as melanoma, lung and breast cancer and lead multiple trials in both primary brain tumors and metastatic disease. I am interested in providing novel care to my patients while maintaining quality of life.

Certifications and Licenses

Neurology

Training Experience

2008Internship, Evanston Hospital
2011Residency, Northwestern University, McGaw Medical Center
2012Fellowship, Northwestern University, McGaw Medical Center

Education/Academic qualification

MD, Northeastern Ohio University

… → 2007

Research interests

  • Brain Cancer / Nervous System Cancer
  • Neuro-Oncology
  • Neurology

Fingerprint Dive into the research topics where Priya U Kumthekar is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 15 Similar Profiles
temozolomide Medicine & Life Sciences
Glioma Medicine & Life Sciences
Glioblastoma Medicine & Life Sciences
Neoplasm Metastasis Medicine & Life Sciences
Brain Neoplasms Medicine & Life Sciences
Central Nervous System Medicine & Life Sciences
Breast Neoplasms Medicine & Life Sciences
Therapeutics Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2010 2025

DRUG M16-438 - A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Anti-Tumor Activity of ABBV-321 in Subjects with Advanced Solid Tumors Associated with Overexpression of the Epidermal Growth Factor Receptor (EGFR) or its Ligands

Kumthekar, P. U.

AbbVie Inc.

10/18/19 → 10/18/22

Project: Research project

DRUG M16-534 - Study Evaluating Ocular Side Effects of Depatux-M (ABT-414)

Kumthekar, P. U.

AbbVie Inc.

5/14/19 → 5/14/22

Project: Research project

Alliance for Clinical Trials in Oncology (Alliance Executive Officer)

Kumthekar, P. U.

Brigham and Women's Hospital, National Cancer Institute

4/4/19 → 2/28/25

Project: Research project

Organized Financing
Industry
Clinical Trials

DRUG ANG1005-CLN-07 - A Randomized Open-Label, Multi-Center Pivotal Study of ANG1005 Compared with Physician’s Best Choice in HER2-Negative Breast Cancer Patients with Newly Diagnosed Leptomeningeal Carcinomatosis and Previously Treated Brain Metastases

Kumthekar, P. U.

Angiochem Inc.

4/1/19 → 4/1/22

Project: Research project

Prot#17-546: NU DF18C03 - A Phase II Study of Atezolizumab in Combination with Pertuzumab Plus High-Dose Trastuzumab for the Treatment of Central Nervous System Metastases in Patients with Her2-Positive Breast Cancer

Kumthekar, P. U.

Dana Farber Cancer Institute, Genentech, Inc.

3/26/19 → 3/26/22

Project: Research project

Research Output 2013 2019

A review of eligibility for patients with central nervous system (CNS) metastases from non-small cell lung cancer (NSCLC) in immunotherapy clinical trials

Shaikh, S. S., Kumthekar, P. U. & Mohindra, N. A., Aug 15 2019, In : Journal of Neuro-Oncology. 144, 1, p. 235-237 3 p.

Research output: Contribution to journal › Letter

Non-Small Cell Lung Carcinoma
Immunotherapy
Central Nervous System
Clinical Trials
Neoplasm Metastasis
3 Citations (Scopus)

Comparison of biomarker assays for EGFR: Implications for precision medicine in patients with glioblastoma

Lassman, A. B., Roberts-Rapp, L., Sokolova, I., Song, M., Pestova, E., Kular, R., Mullen, C., Zha, Z., Lu, X., Gomez, E., Bhathena, A., Maag, D., Kumthekar, P., Gan, H. K., Scott, A. M., Guseva, M., Holen, K. D., Ansell, P. J. & van den Bent, M. J., Jun 1 2019, In : Clinical Cancer Research. 25, 11, p. 3259-3265 7 p.

Research output: Contribution to journal › Article

Open Access
Precision Medicine
Glioblastoma
Fluorescence In Situ Hybridization
RNA Sequence Analysis
Biomarkers

ENvironmental dynamics underlying responsive extreme survivors (ENDURES) of glioblastoma: A multidisciplinary team-based, multifactorial analytical approach

Johnston, S. K., Whitmire, P., Massey, S. C., Kumthekar, P. U., Porter, A. B., Raghunand, N., Gonzalez-Cuyar, L. F., Mrugala, M. M., Hawkins-Daarud, A., Jackson, P. R., Hu, L. S., Sarkaria, J. N., Wang, L., Gatenby, R. A., Egan, K. M., Canoll, P. & Swanson, K. R., Aug 1 2019, In : American Journal of Clinical Oncology: Cancer Clinical Trials. 42, 8, p. 655-661 7 p.

Research output: Contribution to journal › Article

Glioblastoma
Survivors
Survival
Brain Neoplasms
Neoplasms
1 Citation (Scopus)

Lifetime occurrence of brain metastases arising from lung, breast, and skin cancers in the elderly: A SEER-Medicare study

Ascha, M. S., Ostrom, Q. T., Wright, J., Kumthekar, P. U., Bordeaux, J. S., Sloan, A. E., Schumacher, F. R., Kruchko, C. & Barnholtz-Sloan, J. S., May 1 2019, In : Cancer Epidemiology Biomarkers and Prevention. 28, 5, p. 917-925 9 p.

Research output: Contribution to journal › Article

Skin Neoplasms
Medicare
Lung Neoplasms
Epidemiology
Breast Neoplasms

Long-term glioblastoma survival following recovery from cytomegalovirus colitis: A case report

Lamano, J. B., Quaggin-Smith, J. A., Horbinski, C. M., Tate, M. C., Grimm, S. A., Kumthekar, P. U. & Bloch, O., Jun 2019, In : Journal of Clinical Neuroscience. 64, p. 18-21 4 p.

Research output: Contribution to journal › Article

Colitis
Glioblastoma
Cytomegalovirus
temozolomide
Survival